Antisense Pharma is a biopharmaceutical company committed to researching, developing and marketing innovative medicines. Our drugs enable targeted treatment of aggressive tumor diseases. Our main objective is to extend the life expectancy of patients considerably and, at the same time, improve their quality of life.
Founded in 1998, the company is located at the BioPark in Regensburg – one of the most successful biotechnology centers in Germany. Our executive management has many years of entrepreneurial experience, expertise in the biopharmaceutical sector and a sound medical and scientific background. It is supported by a dedicated team with broad experience in the development, approval and marketing of new medicines.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 07/01/11 | Other | 11M | Unknown |
News
Life sciences briefing: Wednesday, Dec. 19, 2007
December 19, 2007 7:34 pm
TODAY’S HEADLINES: Gene-silencing developer Santaris raises €20M (PDF release) Consumer-driven healthcare manager RedBrick Health prescribed $15M (release) Cardiac Dimensions takes… Continue reading ⟩
Life sciences briefing: Wednesday, Dec. 5, 2007
December 5, 2007 1:52 pm
Featured companies: AxoGen, Cognition Therapeutics, Ester Neurosciences, Gene Security Network, HealthTalk, MPM Capital, Revolution Health, SparkPeople UPDATING: Expanded items on… Continue reading ⟩
New biotech startup Excaliard Pharma raises $16M for a fresh stab at antisense drugs
November 27, 2007 8:56 pm
(UPDATED: See below.) “Antisense” drugs that aim to shut down disease-related genes have long been out of favor, and these… Continue reading ⟩